新規抗ＰＤ−１抗体 - Wuxi Biologics (Cayman) Incorporated

Title:

新規抗ＰＤ−１抗体

Document Type and Number:

Japanese Patent JP6883579

Kind Code:

B2

Abstract:

The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.

More Like This:

JP6714620	Targeted / immunomodulatory fusion proteins and methods for making them
WO/2022/028354	ANTI-NGF ANTIBODY AND ANTIGEN-BINDING FRAGMENT THEREOF, PREPARATION METHOD THEREROFR, AND APPLICATION THEREOF
JP2019530456	Universal platform for CAR therapy targeting novel antigenic signatures of cancer

Inventors:

Tsuen, Yong
lysine
Chen, Chi Shen

Application Number:

JP2018526985A

Publication Date:

June 09, 2021

Filing Date:

August 11, 2016

Export Citation:

Click for automatic bibliography generation Help

Assignee:

Wuxi Biologics (Cayman) Incorporated
Open Monoclonal Technology, Incorporated

International Classes:

C12N15/13; A61K39/395; A61P31/12; A61P35/00; A61P37/04; A61P43/00; C07K16/28; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/06; C12N15/63

Domestic Patent References:

JP2010500872A
JP2006521783A
JP2009155338A

Foreign References:

WO2013059524A1
WO2012056407A1
US20150203579

Attorney, Agent or Firm:

Hidesaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto

Previous Patent: テトラサイクリンの塩

Next Patent: 飲料を準備するための飲料準備マシン